Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Losmapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK11 known ✓ | Q15759 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 12/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | PRKACG | P22612 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 1.00 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losmapimod SCHEMBL29888732 | 1.00 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| Losmapimod SCHEMBL1070401 | 1.00 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448678 | 0.93 | MAPK14 (0.86) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20883154 | 0.92 | MAPK14 (0.85) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20460539 | 0.92 | MAPK14 (0.84) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427536 | 0.91 | MAPK14 (0.84) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3427034 | 0.91 | MAPK14 (0.83) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3409067 | 0.90 | MAPK14 (0.82) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3431414 | 0.89 | MAPK14 (0.82) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL3429819 | 0.89 | MAPK14 (0.80) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 822 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-12485157-B2 | Method of treating COVID-19 | PFIZER INC. (US) | 2025-12-02 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12370180-B2 | P38 map kinase inhibitors for treating Friedreich's ataxia | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-07-29 | — | — | US | claimed |
| EP-4587558-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | Fate Therapeutics, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250221947-A1 | METHODS FOR TREATING A CORONAVIRUS INFECTION USING VALPROIC ACID AND DOCOSAHEXAENOIC ACID | UNIV TEXAS (US) | 2025-07-10 | — | — | US | claimed |
| US-20250191770-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2025-06-12 | — | — | US | claimed |
| CN-119948152-A | Methods and compositions for inducing hematopoietic cell differentiation | 菲特治疗公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| EP-3980012-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-04-13 | — | — | EP | claimed |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | ATRIVA THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | US | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| US-11266700-B2 | Compositions and methods for treating immune disorders using immune modulating Lactococcus bacteria strains | EVELO BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | claimed |
| WO-2022047311-A1 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | PFIZER INC. (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | claimed |
| WO-2022034031-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2022-02-17 | — | — | WO | claimed |
| EP-3953361-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF COVID-19 | Pfizer Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| WO-2022020364-A1 | PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022020326-A1 | VEILLONELLA PARVULA STRAIN AS AN ORAL THERAPY FOR NEUROINFLAMMATORY DISEASES | EVELO BIOSCIENCES, INC. (US) | 2022-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485157-B2 | Method of treating COVID-19 | ACE2, ACE, TMPRSS2 | MAPK14 4036/4885MAPK11 4295/4885CYP2C9 642/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | MAPK14 1005/4885MAPK11 1734/4885CYP2C9 4884/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885MAPK11 1894/4885CYP2C9 3485/4885 |
| US-20220096590-A1 | NOVEL-ANTI-INFECTIVE STRATEGY AGAINST INFLUENZA VIRUS AND S. AUREUS COINFECTIONS | MAPK1, MAP2K1, MAP2K6 | MAPK14 14/4885MAPK11 55/4885CYP2C9 3464/4885 |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | MAPK14 3891/4885MAPK11 2811/4885CYP2C9 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.